1334540-22-5

Upstream product

• 604-69-3 β-D-glucose pentaacetate 
• 1334540-38-3 S-(2-methyl-5-tert-butylphenyl)-4,6-O-benzylidene-3-O-tertbutyldimethylsilyl-1-thio-?-D-glucopyranoside 
• 1334540-35-0 (2-methyl-5-tert-butylphenyl) 4,6-O-benzylidene-1-thio-β-D-glucopyranoside 
• 1334540-33-8 (2-methyl-5-tert-butylphenyl) 2,3,4,6-tetra-O-acetyl-1-S-β-D-thioglucopyranoside 
• 61881-19-4 2,2,2-trifluoro-N-phenyl-acetimidoyl chloride 
• 1421758-31-7 (2-methyl-5-tert-butylphenyl) 1-thio-β-D-glucopyranoside 
• 1334540-20-3 S-(2-methyl-5-tert-butylphenyl) 2-O-benzoyl-4,6-O-benzylidene-3-O-fluorenylmethoxycarbonyl-1-thio-β-D-glucopyranoside 
• 1334540-53-2 S-(2-methyl-5-tert-butylphenyl) 2-O-benzoyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 
• 1334540-50-9 S-(2-methyl-5-tert-butylphenyl) 2-O-benzoyl-4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-1-thio-β-D-glucopyranoside 

Relevant academic research and scientific papers

Progress toward developing a carbohydrate-conjugate vaccine against Clostridium difficile ribotype 027: Synthesis of the cell-surface polysaccharide PS-I repeating unit

Clostridium difficile strain ribotype 027 is a hypervirulent pathogen that is responsible for recent, severe outbreaks of serious nosocomial infections. As a foundation for the development of a preventative carbohydrate-based vaccine, we have synthesized a pentasaccharide cell wall repeating unit from PS-I unique to this strain, by the linear assembly of four monosaccharide building blocks.